STW:PA:PA-SPDR® MSCI Europe Health Care UCITS ETF (EUR)

ETF | Others |

Last Closing

USD 215.9

Change

+2.30 (+1.08)%

Market Cap

USD 0.68B

Volume

223.00

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

NA

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-01-09 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
JPX4:PA Amundi Index Solutions - Amund..

-0.39 (-0.86%)

USD 61.38B
SPY5:PA SPDR® S&P 500 UCITS ETF EUR

+0.80 (+0.14%)

USD 13.43B
WRD:PA HSBC MSCI World UCITS ETF

+0.04 (+0.10%)

USD 11.05B
SP5C:PA Lyxor S&P 500 UCITS ETF - C-EU..

+0.34 (+0.08%)

USD 9.62B
EQQQ:PA Invesco EQQQ NASDAQ-100 UCITS ..

N/A

USD 8.88B
MEUD:PA Amundi Stoxx Europe 600 UCITS ..

+0.98 (+0.41%)

USD 8.55B
HHH:PA HSBC S&P 500 UCITS ETF

-0.01 (-0.02%)

USD 7.68B
WLD:PA Lyxor UCITS MSCI World D-EUR

+0.27 (+0.08%)

USD 7.63B
LCWD:PA Multi Units Luxembourg - Lyxor..

N/A

USD 6.83B
S500:PA Amundi S&P 500 ESG UCITS ETF A..

+0.18 (+0.11%)

USD 5.48B

ETFs Containing STW:PA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 3.05% 93% A 79% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 3.05% 93% A 79% B-
Trailing 12 Months  
Capital Gain 3.85% 26% F 51% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 3.85% 22% F 47% F
Trailing 5 Years  
Capital Gain 34.13% 55% F 68% D+
Dividend Return N/A N/A N/A N/A N/A
Total Return 34.13% 51% F 64% D
Average Annual (5 Year Horizon)  
Capital Gain 9.19% 56% F 61% D-
Dividend Return 9.19% 53% F 58% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 8.22% 74% C 87% B+
Risk Adjusted Return 111.85% 92% A 96% N/A
Market Capitalization 0.68B 74% C 75% C

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:

There is nothing we particularly dislike